• Dianthus Therapeutics EVP, Head of R&D Simrat Randhawa reported option exercises, acquiring 23,124 common shares on Sept. 1, 2026.
• Same day sales totaled 23,124 shares at weighted average prices of USD 105.19, USD 106.25, USD 106.74.
• Post-transaction holdings: 4,000 common shares directly owned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001992260-26-000009), on September 03, 2026, and is solely responsible for the information contained therein.